Foreign CMOs expand US capacity as pharma supply chains regionalize

Foreign contract manufacturing organizations (CMOs) are accelerating investment in US manufacturing as pharmaceutical companies prioritize supply-chain resilience, regional capacity and greater control over production.

The recent site upgrades, acquisitions and new partnerships signal a shift from cost-driven outsourcing toward integrated, locally anchored models, giving sponsors broader access to end-to-end capabilities while reducing exposure to geopolitical, tariff and technology-transfer risks, according to pharma intelligence company GlobalData.